News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,423 Results
Type
Article (43254)
Company Profile (321)
Press Release (663848)
Section
Business (211773)
Career Advice (2154)
Deals (37020)
Drug Delivery (97)
Drug Development (83840)
Employer Resources (172)
FDA (16567)
Job Trends (15511)
News (358660)
Policy (34317)
Tag
Academia (2607)
Africa (803)
Alliances (51643)
Alzheimer's disease (1189)
Approvals (16488)
Arizona (187)
Artificial intelligence (99)
Asia (40715)
Australia (6442)
Bankruptcy (367)
Best Places to Work (11554)
Biosimilars (72)
Biotechnology (205)
Breast cancer (76)
C2C Services and Suppliers (80003)
California (2152)
Canada (1024)
Cancer (655)
Career advice (1791)
Cell therapy (158)
China (170)
Clinical research (65884)
Collaboration (205)
Colorado (89)
Compensation (114)
Connecticut (92)
COVID-19 (2596)
Cystic fibrosis (80)
Data (482)
Diabetes (106)
Diagnostics (6122)
Drug pricing (90)
Earnings (85810)
Employer resources (148)
Europe (86935)
Events (112117)
Executive appointments (191)
FDA (16878)
Florida (313)
Funding (191)
Gene therapy (117)
GLP-1 (591)
Government (4494)
Healthcare (18946)
Hotbed/Location (492297)
Illinois (282)
Indiana (163)
Infectious disease (2641)
Inflammatory bowel disease (98)
Interviews (335)
IPO (16653)
Job creations (4153)
Job search strategy (1545)
Kansas (94)
Layoffs (435)
Legal (8443)
Lung cancer (130)
Manufacturing (123)
Maryland (448)
Massachusetts (1783)
Medical device (13209)
Medtech (13214)
Mergers & acquisitions (20275)
Metabolic disorders (328)
Michigan (133)
Minnesota (227)
Neuroscience (1386)
New Jersey (667)
New York (671)
NextGen Class of 2024 (6696)
Non-profit (4532)
North Carolina (651)
Northern California (932)
Obesity (200)
Ohio (117)
Opinion (213)
Patents (87)
Pennsylvania (636)
People (58415)
Pharmaceutical (95)
Phase I (20429)
Phase II (28940)
Phase III (21744)
Pipeline (143)
Postmarket research (2670)
Preclinical (8619)
Radiopharmaceuticals (239)
Rare diseases (161)
Real estate (6342)
Regulatory (22459)
Research institute (2379)
Resumes & cover letters (368)
South America (1178)
Southern California (864)
Startups (3778)
Texas (286)
United States (9700)
Vaccines (522)
Washington State (275)
Weight loss (174)
Date
Last 7 days (677)
Last 30 days (2554)
Last 365 days (37501)
2024 (28238)
2023 (40928)
2022 (52113)
2021 (56677)
2020 (55113)
2019 (47824)
2018 (36141)
2017 (33572)
2016 (33169)
2015 (39008)
2014 (32960)
2013 (28078)
2012 (30165)
2011 (30872)
2010 (28890)
707,423 Results for "shionogi pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
October 1, 2024
·
5 min read
Business
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
Akili, Inc. including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. (“Shionogi”), a leading global pharmaceutical company.
April 30, 2024
·
9 min read
Business
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.
May 10, 2024
·
6 min read
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
Shionogi & Co., Ltd. announced the company is responding to the urgent global need for additional antimicrobial research and development by establishing its first discovery laboratory in the U.S., in San Diego, California.
June 3, 2024
·
9 min read
Business
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan.
February 26, 2024
·
7 min read
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
Business
Shionogi Strengthens Regulatory Leadership with the Appointment of Dr. Ramón Polo as Senior Vice President, Head of Regulatory Affairs
Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.
February 5, 2024
·
4 min read
Drug Development
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare.
February 27, 2024
·
10 min read
Business
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.First Commercial Agreement for DispersinB®
Kane Biotech Inc. announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB ® technology.
June 25, 2024
·
3 min read
Deals
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics, Inc. today announced that it has entered into a definitive merger agreement (“Merger Agreement”) with Insud Pharma, S.L.
June 26, 2024
·
10 min read
1 of 70,743
Next